← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	3,327	+9	+0.3%	$296B
2	2 Pfizer PFE $169B	2,735	+59	+2%	$146B
3	3 AbbVie ABBV $506B	2,677	+62	+2%	$133B
4	4 Merck MRK $365B	2,675	-13	-0.5%	$144B
5	5 Bristol-Myers Squibb BMY $125B	2,371	+1	+0%	$109B
6	6 Amgen AMGN $238B	2,197	-21	-0.9%	$106B
7	7 Gilead Sciences GILD $198B	1,546	-21	-1%	$68.5B
8	8 Novartis NVS $287B	1,120	-16	-1%	$19.8B
9	9 Regeneron Pharmaceuticals REGN $82.6B	972	+48	+5%	$49.6B
10	10 GSK GSK $98.6B	800	+24	+3%	$12.7B
11	11 AstraZeneca AZN $259B	772	+15	+2%	$26.1B
12	12 DELISTED Exact Sciences EXAS	625	-21	-3%	$19.2B
13	13 Incyte INCY $23.1B	523	+30	+6%	$17.2B
14	14 Jazz Pharmaceuticals JAZZ $13.9B	505	+64	+15%	$10.2B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	477	-24	-5%	$25.6B
16	16 Guardant Health GH $22.3B	417	-2	-0.5%	$11.1B
17	17 Exelixis EXEL $15.5B	345	-3	-0.9%	$4.88B
18	18 Natera NTRA $58.1B	342	+18	+6%	$9.69B
19	19 Halozyme HALO $13.8B	315	-21	-6%	$5.89B
20	20 NeoGenomics NEO $2.21B	311	-21	-6%	$5.03B
21	21 Takeda Pharmaceutical TAK $62.7B	305	-12	-4%	$1.6B
22	22 BioNTech BNTX $22.7B	284	+58	+26%	$7.84B
23	23 DELISTED Blueprint Medicines BPMC	281	+17	+6%	$5.15B
24	24 Fate Therapeutics FATE $231M	272	+12	+5%	$8.2B
25	25 BeOne Medicines Ltd ONC $42.2B	268	+15	+6%	$19.1B